The Growing MENA Biologics & Biosimilars Market is in Trends by Rising Healthcare Spending

 MENA Biologics & Biosimilars include recombinant therapeutic proteins and monoclonal antibodies used to treat various chronic and acute conditions such as diabetes, cancer, and autoimmune diseases. Biologics are large, complex molecules or mixtures of molecules, produced from living systems. Biosimilars are biotherapeutic products that are similar to an already approved biological drug that works in a similar manner but are not identical. They offer cost-effective treatment options due to lower prices compared toReference Biologics. The MENA Biologics & Biosimilars Market comprising of biosimilar versions of recombinant human insulin, insulin glargine, interferon beta-1a, filgrastim, etanercept and infliximab among others.

The Global MENA Biologics & Biosimilars Market is estimated to be valued at US$ 578.54 Mn in 2024 and is expected to exhibit a CAGR of 1.1% over the forecast period 2024 to 2030.


Key Takeaways


Key players operating in the Mena Biologics & Biosimilars are AstraZeneca, Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Pfizer Inc. AstraZeneca launched Fasenra, a monoclonal antibody for severe asthma in Saudi Arabia and other MENA markets. Eli Lilly launched Trulicity, a once-weekly GLP-1 agonist for type 2 diabetes treatment across key MENA markets.

The demand for biosimilars is rising in the region due to growing prevalence of chronic diseases and rising healthcare costs. Biosimilars provide a more affordable treatment option for patients. Additionally, governments are encouraging greater use of biosimilars to reduce healthcare expenditure.

Major international pharmaceutical companies are expanding their biosimilars portfolio in the MENA region through collaborations, acquisitions and new product launches. Regional pharmaceutical manufacturers are also developing biosimilar versions of major biologic drugs.

Market key trends

One of the key trends in the MENA Biologics & Biosimilars Market is increasing adoption of single-use bioprocessing technologies. Single-use bioprocessing uses disposable or single-use systems rather than the traditional steel reactors and piping. It offers benefits like reduced risk of cross-contamination, lower capital investment, improved flexibility and speed to meet fluctuating demand. Leading biopharma companies in the region are adopting single-use technologies to optimize their biosimilars production processes.


Porter’s Analysis

Threat of new entrants: High investments required to set up manufacturing facilities increases threat of new entrants.

Bargaining power of buyers: Major buyers are government entities and private hospitals so bargaining power is moderate to high.

Bargaining power of suppliers: Key raw materials are sourced from limited suppliers so suppliers enjoy high bargaining power.

Threat of new substitutes: Continuous innovation and advancements in treatment alternatives poses threat of new substitutes.

Competitive rivalry: Intense competition between existing major players along with regional companies results in high competitive rivalry.

The geographical region where the MENA biologics and biosimilars market in terms of value is concentrated in Gulf Cooperation Council (GCC) countries. The major GCC countries are Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain and Oman. These GCC countries account for more than 60% share of total MENA biologics and biosimilars market value.

The fastest growing region for the MENA biologics and biosimilars market is Algeria. Algeria biologics and biosimilars market is growing at a rapid annual growth rate of around 20% owing to rising healthcare expenditure, prevalence of chronic diseases and development of healthcare infrastructure in the country. The Algerian government supports indigenous biologics and biosimilars production and generic drugs to reduce healthcare costs. This is boosting investments from local and multinational pharmaceutical companies in Algeria biologics and biosimilars market.

Comments

Post a Comment

Popular posts from this blog

Vegan Yogurt Market is Poised for Growth Driven by Rising Health Consciousness

Image
Vegan yogurt is a dairy-free alternative to conventional yogurt made from plant-based milk such as soy, almond, oat, coconut or rice. It provides similar texture and taste to dairy yogurt but without any animal products.Vegan yogurt offers several health advantages over dairy yogurt as it is devoid of lactose, cholesterol and saturated fats. The growing number of people adopting vegan and flexitarian diets has driven the demand for plant-based dairy alternatives like vegan yogurt. The global vegan yogurt market is estimated to be valued at US$ 4.15 Mn in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024 to 2031. Key Takeaways Key players- Met Fods, Cocos Organic, Hain Celestial, EasiYo Product Limited, Danone, General Mills Inc., Stonyfield Far, Inc., Daiya Foods Inc.m Good Karma foods, Inc.m Hudson River Foodsm NANCY'S, Kite Hill, COYO Pty lTd., Nush Foods, Chobani, LLC, Barambah Oraganics Pty Ltd., Blue Diamond Growers, Dean Foodsm General Mills Inc...
Read more

Hypoglycemic Drugs Market is Estimated to Witness High Growth Owing to Increasing Prevalence of Diabetes in the Geriatric Population

Image
Hypoglycemic drugs or anti-diabetic drugs are medications used to treat diabetes mellitus by lowering blood glucose levels. Some key hypoglycemic drugs include insulin, sulfonylureas, metformin, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists. These drugs help control blood sugar levels in diabetics and prevent or delay diabetes-related health complications. The global hypoglycemic drugs market is estimated to be valued at US$ 720.72 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: The growth of the global hypoglycemic drugs market is majorly driven by the increasing prevalence of diabetes in the geriatric population globally. As per estimates, around 1 in every 11 people aged 65 years and above have diabetes. Further, the number of people with diabetes in this age group is anticipated to grow from 25.9 million in 2017 to...
Read more

Clinical Trials Rising with Digital Technologies Adoption

Image
 Clinical trials support services play a vital role in assisting sponsors and life science companies to conduct clinical trials in a precise and well-organized manner.These services assist pharmaceutical companies in patient recruitment, data management, site management, and overall clinical trial management. With rising complexities in clinical trials owing to integration of technologies like telehealth and remote patient monitoring, the demand for these support services is growing substantially. The global Clinical Trials Support Services Market is estimated to be valued at US$ 22.38 Bn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market key trends: The growing adoption of digital technologies across clinical trials is a key trend accelerating the growth of the clinical trials support services market. Digital tools like electronic data capture, clinical trial manag...
Read more